The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients

BACKGROUND: Sepsis and complications to sepsis are major causes of mortality in critically ill patients. Rapid treatment of sepsis is of crucial importance for survival of patients. The infectious status of the critically ill patient is often difficult to assess because symptoms cannot be expressed...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Jens-Ulrik, Lundgren, Bettina, Hein, Lars, Mohr, Thomas, Petersen, Pernille L, Andersen, Lasse H, Lauritsen, Anne Ø, Hougaard, Sine, Mantoni, Teit, Bømler, Bonnie, Thornberg, Klaus J, Thormar, Katrin, Løken, Jesper, Steensen, Morten, Carl, Peder, Petersen, J Asger, Tousi, Hamid, Søe-Jensen, Peter, Bestle, Morten, Hestad, Søren, Andersen, Mads H, Fjeldborg, Paul, Larsen, Kim M, Rossau, Charlotte, Thomsen, Carsten B, Østergaard, Christian, Kjær, Jesper, Grarup, Jesper, Lundgren, Jens D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491622/
https://www.ncbi.nlm.nih.gov/pubmed/18620598
http://dx.doi.org/10.1186/1471-2334-8-91

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491622/
https://www.ncbi.nlm.nih.gov/pubmed/18620598
http://dx.doi.org/10.1186/1471-2334-8-91

Ejemplares similares